Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)
Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)
Physician Assistant - 0.25 AAPA hour(s) of Category I credit
IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit
This activity is intended for obstetricians/gynecologists/women’s health physicians, psychiatrists, family medicine/primary care physicians, internists, public health and prevention officials, nurses, pharmacists, physician assistants, and other members of the healthcare team for women taking opioids in the postpartum period.
The goal of this activity is for learners to be better able to describe incidence and risk factors for postpartum opioid overdose death and other causes of postpartum death in women with opioid use disorder (OUD).
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-128-H08-P).
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 04/14/2024. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive
AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 4/14/2023
Valid for credit through: 4/14/2024
processing....
Women with opioid use disorder (OUD) may be at increased but poorly characterized risk for causes of maternal mortality other than fatal overdose. Most pregnant women with OUD have comorbid depression and anxiety, both strong risk factors for suicide.
They may also have greater risk for homicide, drug-related accidents, or medical complications from OUD, including endocarditis, sepsis, and liver failure. Increased susceptibility to certain obstetric complications may also raise risk for postpartum mortality.
Opioid overdose and other preventable causes are important contributors to postpartum death rates, Medicaid claims data show, particularly in women who have a recent history of OUD, according to research published in Obstetrics and Gynecology.[1]
Opioid overdose deaths account for up to 10% of pregnancy-associated deaths in the United States, and 75% of the deliveries of women with OUD are covered by Medicaid, according to lead author Elizabeth Suarez, PhD, MPH, with the division of pharmacoepidemiology and pharmacoeconomics at Brigham and Women's Hospital and Harvard Medical School in Boston, Massachusetts, and colleagues.
Nearly 5 Million Deliveries StudiedResearchers studied claims data from Medicaid and the National Death Index database in the United States from 2006 to 2013 for 4,972,061 deliveries. They also identified a subgroup of women with a documented history of OUD in the 3 months before delivery.
They found the incidence of postpartum opioid overdose deaths was 5.4 per 100,000 deliveries (95% CI: 4.5, 6.4) among all in the study and 118 per 100,000 (95% CI: 84, 163) among individuals with OUD.
Incidence of all-cause postpartum death was 6 times higher in women with OUD than in all the women studied. Common causes of death of women with OUD were other drug- and alcohol-related deaths (47/100,000); suicide (26/100,000); and other injuries, including accidents and falls (33/100,000).
Risk factors strongly linked with postpartum opioid overdose death included mental health and other substance use disorders.
Medication Significantly Lowers Death RiskThe authors also documented the benefit of buprenorphine or methadone for OUD.
For women with OUD who used medication to treat opioid use disorder (MOUD) postpartum, odds for opioid overdose death were 60% lower (odds ratio [OR] 0.4 [95% CI: 0.1, 0.9]).
As important as use of MOUD, Marcela Smid, MD, MS, wrote in an accompanying editorial,[2] is noting that 80% of the women in this study who died of opioid overdoses had contact with a healthcare provider before death.
"Both of these results indicate that we have the means and opportunity to prevent these deaths," wrote Smid, with the division of maternal fetal medicine, University of Utah Health in Salt Lake City, Utah.
Dismal Numbers on Obstetricians/Gynecologists Trained to Prescribe MedicationsShe pointed out some barriers, however. Most clinicians, she noted, lack time and training to prescribe buprenorphine, and in 2019, fewer than 2% of obstetricians/gynecologists (Ob/Gyns) who accept Medicaid were able to prescribe it.
Her charge to Ob/Gyns: "We need to help identify individuals who are at high risk of OUD or opioid overdose by screening."
A validated screening tool should be used at prenatal and postpartum appointments.
On a bigger scale, she urged Medicaid to be expanded for a full year postpartum through the American Rescue Act's State Plan Amendment, something only 28 states and Washington, DC, have done so far.
Smid pointed out some good news, however: The Biden Administration signed the Consolidated Appropriations Act 2023, which eliminated the "X" waiver.
Now all clinicians who have a Drug Enforcement Administration (DEA) registration that includes Schedule III authority can prescribe buprenorphine for OUD if applicable state law allows it.
That calls for medical schools and residency programs to prioritize addiction medicine as a core competency, Smid advised.
Getting Naloxone to Patients, FamiliesOne of the potential interventions the study authors suggested is providing naloxone prescriptions and training to pregnant and postpartum women who have a substance use history and to their partners and significant others.
Mishka Terplan, MD, MPH, explained, "It's one thing to write a prescription; it's another thing for the person to actually get the medication."
"What can we do? We can think about how to get naloxone into people's hands at discharge from the hospital after they give birth, instead of prescribing. That would mean that health systems need to prioritize this," he said. "We give people discharge medications all the time."
Still, naloxone cannot be seen as the answer, he said.
He compared it to defibrillators in public places, which are for rescues, not reversing a population problem.
The best help, he says, will be continuation of treatment.
"Addiction is a chronic condition," he says, "but often we only provide episodic care. We see that particularly in pregnancy. Once the pregnancy is finished, there's not categorical continuation of insurance."
Even if you do have insurance, it is hard to find a clinic that is family friendly, he noted.
Problem Probably UnderstatedHe also said that although the study was well done given the data available, he is frustrated that researchers still have to depend on billing data and cannot capture factors such as child care availability, living wages, and continuation of health insurance. In addition, not everyone is coded correctly for OUD.
"It's all Medicaid, so it's only people who continued with care," he pointed out. That means these numbers may actually underrepresent the problem.
Still, he said, it is important to realize the magnitude of deaths this study does highlight in this population. In people with OUD in the postpartum period, the deaths are more than 1 in 1000.
"That should be alarming," Terplan said. "That's a very big number from a public health perspective."
Coauthor Kathryn J. Gray received payment from Aetion Inc.; BillionToOne; and Roche. Funds were paid to the University of Utah for Smid from Alydia Inc. for being the site principal investigator for a study of the JADA device, and from Gilead Sciences, Inc. for Smid's study of hepatitis C in pregnancy; she was also a consultant for Organon and Rhia Ventures. Terplan reports no relevant financial relationships.